PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
Rhea-AI Summary
PacBio (NASDAQ: PACB) will report first quarter 2026 financial results and host a conference call on Thursday, May 7, 2026 at 4:30 p.m. ET (1:30 p.m. PT). The call will be webcast and available on the company's investor website.
Live listen and replay access are provided via the investor site at https://investor.pacificbiosciences.com/, toll-free dial-in 1-888-349-0136, and international dial-in 1-412-317-0459.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – PACB
On the day this news was published, PACB gained 3.68%, reflecting a moderate positive market reaction. This price movement added approximately $19M to the company's valuation, bringing the market cap to $526.99M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves: DCTH +1.01%, SENS +1.62%, SRDX +0.26%, CTKB +1.52%, RXST -0.69%. Momentum scanner only flags BFLY modestly up, indicating no clear, coordinated sector reaction to this earnings-date notice.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Earnings date notice | Neutral | -7.4% | Set date and time for Q4 and full-year 2025 earnings call. |
Prior earnings-date scheduling news for PACB was followed by a negative move of about -7.39%, indicating the market has previously treated such notices cautiously.
In the past months, PacBio has combined strategic collaborations and governance changes with regular investor communications. A prior earnings-date announcement on Jan 27, 2026 for Q4 and full-year 2025 results led to a -7.39% move over 24 hours. Against that backdrop, today’s notice setting the Q1 2026 earnings call date continues the cadence of formal updates ahead of detailed financial disclosures.
Historical Comparison
Past earnings-date announcements saw an average -7.39% move over 24 hours. Today’s Q1 2026 scheduling update fits this pattern of neutral logistics news preceding the actual financial results.
Tag-specific history shows a prior notice for Q4/FY 2025 results; today’s Q1 2026 call date continues PacBio’s regular sequence of earnings-date announcements.
Regulatory & Risk Context
PacBio has an effective Form S-3ASR shelf registration dated Feb 25, 2026, allowing offerings of common stock, preferred stock, depositary shares, debt, warrants, subscription rights, purchase contracts and units. The filing also covers possible resales by selling stockholders, from which the company will not receive proceeds.
Market Pulse Summary
This announcement sets the timeline for PacBio’s first quarter 2026 results, with the call on May 7, 2026 at 4:30 p.m. ET. Historically, an earlier earnings-date notice was followed by a -7.39% move, indicating markets sometimes reposition around these updates. Investors may monitor the upcoming call in the context of an effective S-3 shelf and recent insider net selling when evaluating how new financial details affect risk-reward.
AI-generated analysis. Not financial advice.
MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
The call will be webcast and may be accessed on PacBio’s website at https://investor.pacificbiosciences.com/.
Date: Thursday, May 7, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
